Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Cervantes, A.
Macarulla, T.
Martinelli, E.
Rodriguez-Braun, E.
Ciardiello, F.
Stroh, C.
Nippgen, J.
Baselga, J.
Tabernero, J.
机构：
[1] Univ Valencia, Hosp Clin, Valencia, Spain
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Univ Naples 2, Naples, Italy
[4] Merck KGaA, Darmstadt, Germany
[5] Ciutat Sanitaria Vall dHebron, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4129
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Molecular profiling of the CAPRI GOIM trial in KRAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts): Cetuximab plus FOLFIRI followed by FOLFOX4 ± cetuximab
    Ciardiello, F.
    Normanno, N.
    Maiello, E.
    Martinelli, E.
    Troiani, T.
    Rachiglio, A. M.
    Giuliani, F.
    Pisconti, S.
    Barone, C.
    Colucci, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S14 - S14
  • [2] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [3] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [4] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) plus BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
    Torrecillas, L.
    Vargas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A469 - A470
  • [6] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Bodoky, G.
    Kyung Roh, J.
    Folprecht, G.
    Park, Y. S.
    Van Laethem, J. L.
    Raoul, J. L.
    Ciardiello, F.
    Lebrun, P.
    Rougier, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 235
  • [8] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
  • [9] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    Van Cutsem, E.
    Lang, I.
    D'haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] RELATIONSHIP BETWEEN KRAS STATUS AND EFFICACY OF FOLFOX6+CETUXIMAB OR FOLFIRI plus CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): THE CECOG/CORE1.2.001 TRIAL
    Ocvirk, J.
    Vrbanec, D.
    Beslija, S.
    Koza, I
    Ciuleanu, T.
    Papamichael, D.
    Wrba, F.
    Messinger, D.
    Zielinski, C.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2009, 20 : 17 - 17
12345